A comparison of six OCT devices

Article

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

In a head-to-head comparison of six OCT devices, the Spectralis spectral domain OCT (Heidelberg Engineering) showed the lowest co-efficient of variation in a test-retest study.

The study, conducted by Dr Ute Wolf-Schnurrbusch and colleagues from the University of Bern, compared central retinal thickness (CRT) measurements in healthy eyes using different commercially available OCT devices and then compared the intersession reproducibility of the measurements. The instruments used were: the Stratus OCT (Carl Zeiss Meditec), SOCT Copernicus (Reichert/Optopol Technology), Spectral OCT/SLO (Opko/OTI), RTVue-100 (Optovue Corporation), Spectralis HRA+OCT and Cirrus HD-OCT (Carl Zeiss Meditec).

The study found that CRT measurements differed significantly between the various devices, with the Spectralis and Cirrus HD-OCT demonstrating higher values than all other instruments. The Spectralis was the only device with a coefficient of variation below 1.0 and the only instrument with a Smallest Measurable Change of less than 2 microns.

“The high repeatability of the Spectralis HRA+OCT measurements is most likely related to the unique feature of the system that allows eye tracking during the scanning process and automatic recognition of the exact same scan location for follow-up examination,” commented Dr Wolf-Schnurrbusch in a Heidelberg press release. “By using this feature for all follow-up scans with the Spectralis HRA+OCT we could minimise extrinsic factors, such as patient fixation and the operator’s ability to consistently place the macular grid over the same points during each scan.”

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.